Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 862 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit Hyperactivity Disorder (ADHD) Clear all
Completed Phase 2 Interventional

Open-Label, Extension Study to 810P202

NCT01416064
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD in Children
Interventions
Molindone
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

NCT03676725
View directory record Official record
Conditions
ADHD, PMS
Interventions
Lidocaine gel
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 30, 2026, 5:29 PM EDT
Completed No phase listed Observational

Genetic Aspects of Neurologic and Psychiatric Disorders

NCT00001544
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Bipolar Disorder, Mental Disorder Diagnosed in Childhood, Mental Retardation, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
1,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-9855 Mass Balance Study

NCT01924143
View directory record Official record
Conditions
ADHD, Fibromyalgia
Interventions
TD-9855
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional

A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2)

NCT01490307
View directory record Official record
Conditions
Substance Use, Conduct Disorder, Depression, Anxiety
Interventions
Family Check-Up
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
Not listed
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

NCT01709695
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride XR, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
8 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

A Clinic-based Prevention Program for Families of Depressed Mothers

NCT00149812
View directory record Official record
Conditions
Depression, Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Interventions
Family Functioning Intervention
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
8 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder

NCT00829881
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Betahistine Hydrochloride, Placebo Capsule
Drug
Lead sponsor
P2D, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 30, 2026, 5:29 PM EDT
Recruiting Phase 1 Interventional

Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

NCT07226219
View directory record Official record
Conditions
Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Extended-Release Methylphenidate
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges

NCT02766101
View directory record Official record
Conditions
Autistic Disorder, Attention Deficit and Disruptive Behavior Disorders, Anxiety Disorders, Mood Disorders, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Aerobic Exergaming PE Curriculum, Standard PE
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
7 Years to 18 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 30, 2026, 5:29 PM EDT
Active, not recruiting Not applicable Interventional

A Trial of Two-Week Brain Stimulation for Teenagers With ADHD

NCT05102864
View directory record Official record
Conditions
ADHD
Interventions
Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex
Device
Lead sponsor
Bradley Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 30, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

NCT01017263
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
Interventions
Lis-dexamphetamine
Drug
Lead sponsor
Duke University
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Results available

Attention Deficit Disorder Medication Response Study

NCT01727414
View directory record Official record
Conditions
ADHD - Inattentive Type, ADHD - Combined Type
Interventions
OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT00500149
View directory record Official record
Conditions
ADHD
Interventions
Vyvanse (lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
9
States / cities
Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Using an Online Patient Monitoring System to Improve Care for Children With Chronic Conditions

NCT02097355
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Asthma, Autism Spectrum Disorder, Depression, Epilepsy
Interventions
TriVox for clinical care
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
946 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Evaluating Stress Management Strategies Within the School Readiness Parenting Program

NCT06626750
View directory record Official record
Conditions
Parenting, Stress, Disruptive Behavior Disorder, Parent-Child Relations, ADHD
Interventions
Summer Treatment Program for Pre-Kindergarteners and Kindergarteners, School Readiness Parenting Program (SRPP), Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
4 Years to 6 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 30, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

NCT00367835
View directory record Official record
Conditions
ADHD
Interventions
SPD503 (Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Phoenix, Arizona • El Centro, California • Rolling Hills Estates, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 30, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

NCT05099874
View directory record Official record
Conditions
Sickle Cell Disease, Attention Deficit, Cognitive Deficit in Attention
Interventions
EndeavorRx
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Improving Emotion Regulation in Adolescents With ADHD

NCT03733548
View directory record Official record
Conditions
Adhd
Interventions
RELAX
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT00566449
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, JNJ-31001074
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Irvine, California • Lafayette, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Efficacy of Neuro+ Attention Training

NCT02642055
View directory record Official record
Conditions
ADHD
Interventions
Neuro+ Attention Training, Treatment as Usual
Behavioral · Other
Lead sponsor
Neuro+
Industry
Eligibility
8 Years to 13 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 30, 2026, 5:29 PM EDT
Not listed Phase 4 Interventional

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

NCT02677519
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 30, 2026, 5:29 PM EDT